NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Price Target & More

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) released its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.53 by $0.08. The biotechnology company earned $44 million during the quarter, compared to the consensus estimate of $40.77 million. Enanta Pharmaceuticals had a return on equity of 18.50% and a net margin of 31.60%. Enanta Pharmaceuticals's quarterly revenue was up 388.9% on a year-over-year basis. During the same period last year, the business posted ($0.28) EPS. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Enanta Pharmaceuticals.

5 brokerages have issued 12-month price targets for Enanta Pharmaceuticals' stock. Their predictions range from $36.00 to $135.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $79.1667 in the next year. This suggests that the stock has a possible downside of 34.6%. View Analyst Ratings for Enanta Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Enanta Pharmaceuticals include Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR), Loxo Oncology (LOXO), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG) and Ligand Pharmaceuticals (LGND).

Media headlines about ENTA stock have been trending somewhat negative this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Enanta Pharmaceuticals earned a news impact score of -0.06 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 47.53 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Enanta Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.10%), Fisher Asset Management LLC (0.08%) and Xact Kapitalforvaltning AB (0.01%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Fisher Asset Management LLC. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda and Paul J Mellett. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was acquired by a variety of institutional investors in the last quarter, including Xact Kapitalforvaltning AB. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $121.02.

Enanta Pharmaceuticals has a market capitalization of $2.37 billion and generates $102.81 million in revenue each year. The biotechnology company earns $17.71 million in net income (profit) each year or $0.91 on an earnings per share basis. Enanta Pharmaceuticals employs 89 workers across the globe.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]